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| INTRODUCTION
Cerebral cavernous malformations (CCM) are angiographically occult clusters of enlarged and tightly packed blood vessels of the venous-capillary bed. Due to disorganized tight and adherens junctions between the lining endothelial cells (ECs), CCMs tend to leak into the neighboring brain tissue. Such intracranial hemorrhages from CCMs can lead to focal neurological deficits, epileptic seizures, and recurrent headaches (Draheim, Fisher, Boggon, & Calderwood, 2014; Spiegler, Rath, Paperlein, & Felbor, 2018) . A hereditary etiology has first been assumed by H. Kufs in 1928 who described CCMs in a father-daughter duo (Kufs, 1928) . Several decades later, three CCM disease genes have been identified: CCM1 (KRIT1; OMIM: *604214) (Laberge-le Couteulx et al., 1999; Sahoo et al., 1999) , CCM2 (Malcavernin; OSM; *607929) (Denier et al., 2004; Liquori et al., 2003) , and CCM3 (PDCD10, TFAR15; *609118) (Bergametti et al., 2005) . The familial form (OMIM 116860, 603284, 603285) is inherited in an autosomal-dominant manner and usually presents with multiple CCMs that are thought to occur after a second somatic mutation within CCM1, CCM2, or CCM3 in the endothelial compartment (Akers, Johnson, Steinberg, Zabramski, & Marchuk, 2009; Gault, Shenkar, Recksiek, & Awad, 2005; McDonald et al., 2014) .
No targeted CCM therapies are available yet and our understanding of the basic mechanisms that initiate CCM formation and growth is still incomplete. Recent in vitro and in vivo studies suggested that clonal expansion of CCM3-deficient ECs might be a key feature of CCM3 biology (Detter, Snellings, & Marchuk, 2018; Schwefel et al., 2019) . However, this novel model of clonal CCM evolution has neither been directly validated for CCM1 nor in a patient-specific context. Blood outgrowth endothelial cells (BOECs) are a perfect tool to answer this question in a personalized disease model. BOECs are fully differentiated, true ECs that can be established from peripheral or cord blood samples by culturing mononuclear cells in an endothelial-supportive medium on collagen-coated plates (Chong, Ng, & Chan, 2016; Hebbel, 2017; Lin, Weisdorf, Solovey, & Hebbel, 2000) . BOECs originate from circulating endothelial colony-forming cells (ECFCs), demonstrate enhanced proliferative properties, and high phenotypic stability (Hirschi, Ingram, & Yoder, 2008; Martin-Ramirez, Hofman, Biggelaar, Hebbel, & Voorberg, 2012) . Of note, CRISPR/Cas9-mediated gene disruption in human ECs has first been demonstrated in outgrowth ECs derived from cord blood ECFCs. Abrahimi and co-workers used lentiviral vectors for CRISPR/Cas9 delivery and efficiently inactivated the human CIITA gene which encodes for an MHC class II transactivator (Abrahimi et al., 2015) .
Using a non-viral and plasmid-free CRISPR/Cas9 approach, we here demonstrate that not only CCM1 gene ablation but also precise gene correction is feasible in hard-to-transfect primary ECs. In a patient-specific cell culture model of Knudson's two-hit hypothesis, we show for the first time that it is the acquisition of a compound heterozygous second CCM1 mutation which leads to a clonogenic survival advantage.
| MATERIALS AND METHODS

| Editorial policies and ethical considerations
The patient participated in this study with written informed consent according to the German Gene Diagnostic Act and approval of the local ethics committee (University Medicine Greifswald, Germany; No.: BB 047/14a).
| Generation of blood outgrowth endothelial cells
Blood outgrowth ECs were established from 30 ml peripheral blood as described (Martin-Ramirez et al., 2012) . In brief, mononuclear cells were separated from whole blood using Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK) and maintained in EGM-2 medium (Lonza, Basel, Switzerland) supplemented with 18% fetal calf serum (FCS, Thermo Fisher Scientific, Waltham, Massachusetts, USA) on collagen I-coated plates (Ibidi, Martinsried, Germany).
| In vitro studies
Immunofluorescent staining was performed with cells that had been fixed on 96-well plates, permeabilized, and washed several times. The following antibodies were used: monoclonal mouse anti-human CD31 (BBA7, R&D Systems, Minneapolis, MN), polyclonal rabbit anti-SM22α (ab14106, Abcam, Cambridge, UK), monoclonal mouse anti-human CD146 (MAB932, R&D Systems), polyclonal rabbit antihuman CD34 (HPA036723, Sigma-Aldrich, St. Louis, MO), polyclonal rabbit anti-KLF4 (PA5-27441, Thermo Fisher Scientific), secondary goat anti-mouse IgG antibody, Alexa Fluor 488 (A-11029, Thermo Fisher Scientific), and goat anti-rabbit IgG antibody, Alexa Fluor 555 (A-21429, Thermo Fisher Scientific). Cell nuclei were stained with DAPI (D9542, Sigma-Aldrich) and samples were overlayed with mounting medium (50001, Ibidi) prior to image acquisition with an EVOS FL microscope (Thermo Fisher Scientific). Factin was stained with phalloidin (Abcam). Spheroid sprouting was performed as described (Spiegler et al., 2016) . Technologies (IDT), Coralville, Iowa, US) targeting the patientspecific variant c.2012delA located in exon 18 of the CCM1 gene (LRG_650t1) was determined using IDT's Custom design tool (https ://eu.idtdna.com/site/order/ desig ntool/ index/ CRISPR_ CUSTOM). For cotransfection, a single-strand oligodeoxy- 
| CRISPR/Cas9-mediated gene editing
. The data were analyzed using SeqNext software (JSI Medical Systems, Ettenheim, Germany). Only variants with quality scores ≥30 and combined read frequencies ≥1% were called.
| Subculturing of transfected BOECs
Transfected cell mixtures were subcultured until grown to confluence on a T25 flask. Clonal expansion was accomplished by seeding 0.5 cells/well of a 96-well plate.
To analyze the proportion of cells with different genotypes in the cell mixtures over time, 10% of CCM1-deficient cells harboring c.2012delA and c.2014_2021del alleles were added to the corrected cell mixture, grown, and passaged on 6-well plates. After 16 and 34 days at roughly 90% confluency, the cells were splitted 1:2 with one half used for DNA isolation and amplicon deep sequencing as described above.
| Potential off-target analysis
Possible off-target sites were predicted by the CCTop -CRISPR/Cas9 target online predictor and IDT's CRISPRCas9 Design checker. The six most likely candidate sequences were selected based on the position of mismatches and their genomic location. Amplicons were generated from DNA of cell mixtures after transfection using the following primer combinations: RIMS2 (forward primer 5'-GAGTTCACACATCCACCTCTG-3', reverse primer 5'-GGACAGATGTTTATTGAGCAGC-3'), WDFY3 (forward primer 5'-TGGCTGTTAGAGGAAGTGGA-3', reverse primer 5'-ACAAAGGTAGAGTTGCTGATGG-3'), VASN (forward primer 5'-CTCTGCAGAGTTTTCCCAGG-3', reverse primer 5'-AGAATGGTGGGACTTGGAGC-3'), MAP4K4 (forward primer 5'-GACTTCTCCAGGCATGTGAG-3', reverse primer 5'-CACCTGGAGAAAAGCAGTGA-3'), RP11-179A10.1 (forward primer 5'-AGCTGAAAACTGCACCGATC-3', reverse primer 5'-GTCAGGGCACATCAGGGAT-3'), and ATP13A4 (forward primer 5'-CAGCCCGGATAAGGACT GTA-3', reverse primer 5'-AGACCCCATCAACTGAGG AT-3'). Amplicons were either prepared for deep sequencing as described above or digested using T7 Endonuclease I (New England Biolabs) and analyzed on a Bioanalyzer instrument using Agilent's DNA 1000 kit (Agilent, Santa Clara, CA). For Sanger sequencing, DNA amplicons were purified with ExoSAP-IT (Affymetrix, Santa Clara, CA), marked with BigDye Terminator Cycle Sequencing v3.1 kit (Thermo Fisher Scientific) and sequenced on an ABI 3130XL (Applied Biosystems, Foster City, CA).
| Caspase-3 activity
Fluorometric analysis of Caspase-3 activity was performed using Caspase-3 DEVD-R110 Assay Kit (Biotium; Fremont, CA) according to the manufacturer's instructions after induction of apoptosis with 1 µM staurosporine for 2 hr.
| RESULTS
| Establishment and characterization of patient-derived BOECs
The 31-year-old index case (III:2, Figure 1a ) became symptomatic at the age of 27 with recurrent headaches and epileptic seizures. Two cavernous malformations were identified by magnetic resonance imaging (MRI) in his right and left
frontal lobe. The larger one was resected after symptomatic bleeding. CCMs have also been detected in his symptomatic father (II:2), brother (III:1), and paternal aunt (II:1). Molecular genetic analyses of all three CCM genes revealed the heterozygous one base pair deletion c.2012delA in CCM1 (Figure 1b ) which has not been described in the literature so far. The deletion leads to a frameshift and therefore disrupts part of the C-terminal FERM domain [p.(Asn671Thrfs*36)] which is important for the interaction of CCM1 with binding partners like HEG1 and RAP1 (Figure 1c ) Spiegler et al., 2014) . Apart from this novel CCM1 frameshift variant, another seven nonsense and 14 frameshift mutations within exon 18 of CCM1 have been reported previously in CCM families and are listed as disease-causing in the human gene mutation database (HGMD Professional 2018.4). Consequently, the identified CCM1 variant was classified as pathogenic for CCM according to the ACMG guidelines for variant interpretation (Richards et al., 2015) .
BOECs were established from peripheral blood of the index proband within 21 days. Bright-field microscopy demonstrated the typical cobblestone morphology (Figure 1d ) and immunofluorescence imaging verified strong expression of the endothelial marker proteins CD31/PECAM-1 (Figure 1g ), CD146 ( Figure 1i ) and CD34 (Figure 1k ) with no differences compared to BOECs from a healthy control (Figure 1f,h,j) . In contrast, only very few cells were positively stained for the mesenchymal marker protein SM22α (Figure 1g ). We also tested the ability of the patient-derived cells to form endothelial sprouts which is a distinctive feature between hematopoietic and endothelial progenitor lineages (Medina et al., 2017) (Figure 1e) .
BOECs from healthy controls and the germline mutation carrier could be passaged approximately 18 times consistent with previous reports (Groeneveld et al., 2015; Lin et al., 2000) .
| Efficient gene correction with CRISPR/Cas9
Using a crRNA:tracrRNA:Cas9 RNP approach, we have recently demonstrated that highly efficient gene disruption can be achieved in human ECs (Schwefel et al., 2019) . However, nonviral CRISPR/Cas9-mediated gene corrections that are even more challenging in hard-to-transfect primary ECs have not yet been reported. Thus, we used the patient-derived BOECs in a proof-of-concept study for precise CCM1 gene correction. A crRNA:tracrRNA:Cas9 RNP complex that targeted the c.2012delA CCM1 allele .2%. To demonstrate the specificity of our genome editing approach, six potential off-target loci were screened for CRISPR/Cas9-induced variants. These loci were selected from bioinformatic predictions based on the number and position of mismatches in the crRNA binding site. No off-target mutations were identified by amplicon deep sequencing and T7 endonuclease cleavage assay ( Figure 2d , Table 1 ). Of note, these results demonstrate for the first time that a CRISPR/Cas9 RNP approach can be used for efficient in vitro gene correction in human ECs.
| Characterization of BOECs after
CRISPR/Cas9-mediated CCM1 gene correction and disruption CCM1 inactivation induces profound endothelial dysfunction such as upregulation of the transcription factor KLF4 and increased actin stress fiber assembly (Cuttano et al., 2016; Glading, Han, Stockton, & Ginsberg, 2007; Zhou et al., 2015) .
To address these changes in our personalized disease model, we also used the CRISPR/Cas9 system to induce chronic CCM1 inactivation by targeting the CCM1 wild type allele in patient-derived BOECs. Increased stress fiber formation was observed after complete CCM1 inactivation (CCM1 
| DISCUSSION
Using patient-derived endothelial progenitor cells (EPCs) in a personalized CCM disease model, we here demonstrate that a non-viral and plasmid-free CRISPR/Cas9 approach allows not only efficient gene knockout but also precise CCM1 gene correction in human ECs. In accordance with Knudson's two-hit hypothesis (Knudson, 1971) , the introduction of a somatic CCM1 mutation into the second allele of a CCM1 mutation carrier resulted in a clear phenotype while heterozygosity for the germline variant alone did not. Within a short period of time, CCM1 −/− EPCs dominated the cell culture (Figure 3f ) which likely reflects the early phase of lesion genesis as recently visualized in an inducible Ccm3 mouse model (Detter et al., 2018) . Consequently, our work suggests that the concept of clonal evolution seen after CCM3 inactivation in mice (Detter et al., 2018) and immortalized human umbilical vein ECs (Schwefel et al., 2019 ) also applies to CCM1. The delivery of the CRISPR/Cas9 components into primary endothelial and other hard-to-transfect cells has been a major obstacle for cardiovascular research. Plasmids, lenti-, adeno-or adeno-associated viral vectors have most often been used to achieve sufficient gene knockout rates in ECs (Abrahimi et al., 2015; Cullere, Plovie, Bennett, MacRae, & Mayadas, 2015; Gong et al., 2017; Miao et al., 2018; Wu et al., 2017) . Just recently, we have demonstrated that gene knockouts in human ECs can be established with a crR-NA:tracrRNA:Cas9 RNP approach (Schwefel et al., 2019) . However, effective CRISPR/Cas9-driven gene knock-in or precise single nucleotide corrections have been hampered by low efficiency of homology-directed repair (HDR) strategies when compared to non-homologous end joining (NHEJ)-mediated gene knockout approaches (Mali et al., 2013) . Even with the use of the small molecule L755507 that can enhance HDR efficiency, CRISPR/Cas9-mediated knock-in rates in primary ECs have been reported to be lower than 3% (Yu et al., 2015) . To the best of our knowledge, precise editing of single nucleotide variants (SNV) or small frameshift mutations in primary ECs or endothelial progenitor cells have not yet been reported.
It therefore seems remarkable for CCM but also for cardiovascular research in general that we were able to precisely correct 10% of all patient-derived CCM1 +/− ECs by homology-directed repair in a crRNA:tracrRNA:Cas9 RNP approach. It should be noted that crRNA:tracrRNA:Cas9 RNPs have several advantages when compared to viral or plasmid delivery systems. In particular, the risk of off-target effects is minimized due to the transient expression of RNPs (Kim, Kim, Cho, Kim, & Kim, 2014) . The absence of CRISPR/Cas9-induced variants on the patient's wild type CCM1 allele and of mutations in predicted off-target loci highlights the specificity of our non-viral and plasmidfree approach.
Given that a Knudsonian two-step inactivation of CCM1 in ECs initiates CCM formation in germline mutation carriers (Akers et al., 2009; Gault et al., 2009 Gault et al., , 2005 McDonald et al., 2014; Pagenstecher, Stahl, Sure, & Felbor, 2009) (Malinovskaya et al., 2016) and contribute to endothelial regeneration, vascular stability and de novo formation of functional blood vessels (Banno & Yoder, 2018; Critser & Yoder, 2010) , our results therefore suggest that the therapeutic potential of somatic gene correction in CCM is limited.
